Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02067676 · ClinicalTrials.gov registry record · Phase 1
Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea
A Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT02067676 is a Phase 1 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 48 participants.
The verdict
NCT02067676, a Phase 1 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety of increasing doses of a potential vaccine against Campylobacter with and without Alhydrogel®, an aluminum hydroxide adjuvant. This study will also assess immune responses induced by the vaccine.
Interventions
- BIOLOGICAL Capsule-Conjugate Campylobacter Vaccine (CJCV1)
- DRUG Alhydrogel®, aluminum hydroxide adjuvant (alum)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2014-04-21 |
| Est. Completion | 2016-01-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02067676
The ClinicalTrials.gov registry entry for NCT02067676 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Capsule-Conjugate Campylobacter Vaccine (CJCV1) is the first listed.
NCT02067676 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02067676 about?
NCT02067676 is a clinical study titled "Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea". The purpose of this study is to assess the safety of increasing doses of a potential vaccine against Campylobacter with and without Alhydrogel®, an aluminum hydroxide adjuvant. This study will also assess immune responses induced by the vaccine.
What is the current status of trial NCT02067676?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2014-04-21. Estimated completion is 2016-01-22.
What interventions are being tested in trial NCT02067676?
The interventions under investigation include: Capsule-Conjugate Campylobacter Vaccine (CJCV1) (BIOLOGICAL), Alhydrogel®, aluminum hydroxide adjuvant (alum) (DRUG).
Who is sponsoring clinical trial NCT02067676?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.